Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
Efficacy and Safety of Different Concentrations of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
West China Hospital
200 participants
Mar 8, 2023
INTERVENTIONAL
Conditions
Summary
Bleomycin has nowadays been more and more widely used in the sclerotherapy of LMs, which has been proven to be primarily dose dependent. The investigators aim to compare the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of LMs for pediatric patients.
Eligibility
Inclusion Criteria3
- Male or female participants less than 14 years of age at the time of informed consent/assent form was signed.
- Participants whose parents have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them.
- Participants with LMs of all sites measured and confirmed via imaging at screening, with rapid progression, resluting in obvious symptoms or dysfunction, which could not be radically resected and could be treated by sclerotherapy.
Exclusion Criteria4
- Penicillin allergy.
- Vascular tumors or combined vascular malformations.
- Participants who may have had surgical or sclerotherapy treatment by other hardeners.
- LMs growing slowly, without obvious symptoms or dysfunction, which does not need to be treated prematurely.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06437158